ReviewHerz2023
The COVID-19 pandemic in China: from dynamic zero-COVID to current policy.
Review in Herz, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Monitoring pneumonia onset and severe respiratory infectious diseases using quantitative computed tomography, validation amidst the coronavirus disease 2019 outbreak at the end of 2022 in the Chinese mainland.Journal of thoracic disease · 2026Article
- Epidemiological characteristics and transmission dynamics of COVID-19 outbreaks in China: a four-year retrospective analysis using extended SEIR models.BMC public health · 2026Article
- SARS-CoV-2 wastewater surveillance in a central Chinese metropolis: variant responses and correlation with clinical cases.Frontiers in public health · 2026Article
- Article
- Transcriptomic profiling reveals immune signatures associated with potential COVID-19 susceptibility and a predictive framework in a Chinese cohort.Frontiers in immunology · 2026Article
- Pandemic-Associated Sensitization Patterns and Burden in Chinese Children with Allergic Rhinitis: A Retrospective Phase-Stratified Study.Journal of asthma and allergy · 2026Article
- Article
- Staged identification of CAP in fever patients across epidemic environments: modeling & validation.Scientific reports · 2025Article
- Complications among patients undergoing orthopedic surgery after infection with the SARS-CoV-2 Omicron strain and a preliminary nomogram for predicting patient outcomes.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2025Article
- Bayesian joint spatiotemporal modelling of primary infection and reinfection of HFMD at county level in Jiangsu, China, 2009-2023.BMC public health · 2025Article
- Association between SARS-CoV-2 levels in urban wastewater and reported COVID-19 cases in Changsha, Central China.BMC infectious diseases · 2025Article
- Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China.Journal of thoracic disease · 2025Article
- Observational
- Calculation of COVID-19 disease burden using Monte Carlo simulation with dynamic disability weights and analysis of transmission characteristics.BMC public health · 2025Article
- Diagnostic Delay Among Pulmonary Tuberculosis Patients Before, During and After COVID-19 Pandemic in Yichang City, China: A Longitudinal Study Based on Tuberculosis Surveillance Data.Journal of epidemiology and global health · 2025Article
- Correlation Between the Online Visiting Time and Frequency Increase in Telemedicine Services Offered by Health Care Providers Before, During, and After the COVID-19 Pandemic in China: Cross-Sectional Study.Journal of medical Internet research · 2025Article
- Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on theFrontiers in pharmacology · 2025Article
- Epidemiological trends of influenza A and B in one hospital in Chengdu and national surveillance data (2019-2024).Frontiers in cellular and infection microbiology · 2025Article
- Anxiety and Depressive Symptoms Among Kidney Transplant Recipients in Post-COVID-19 China: Prevalence and Risk Factors.Risk management and healthcare policy · 2025Article
- Echoes of Strain: A Two-Year Longitudinal Study on the Impact of China's Zero-COVID Policy on College Students' Insomnia and Depressive Symptoms.Nature and science of sleep · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On 8 January 2023, after 3 years of pandemic control, China changed its management of COVID-19, applying measures against class B infectious diseases instead of Class A infectious diseases. This signaled the end of the dynamic zero-COVID policy and the reopening of the country. With a population of 1.41 billion, China's reopening policy during the COVID-19 pandemic has been characterized by a scientific, gradual, and cautious approach. Several factors contributed to the reopening policy, including an expansion of healthcare capacity, the widespread promotion and uptake of vaccination, and improved prevention and control mechanisms. According to the latest report from the Chinese Center for Disease Control and Prevention, the number of hospitalized COVID-19 patients in the country reached a peak of 1.625 million on January 5, 2023, and has since continued to decline. As of February 13, the number decreased to 26,000: a reduction of 98.4%. Thanks to the efforts of healthcare workers and society as a whole, the country managed to get through the peak of the epidemic in a stable manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.